Loma Therapeutics

Denmark · owned by Independent (Denmark) · lomatherapeutics.com · 8 vendors

Loma Therapeutics is a Danish biotech startup developing a cutting-edge HPV-targeted immunotherapy (Loma001) to treat and prevent HPV-induced cancers, including head and neck, cervical, anal, and penile cancers. Their approach uses replication-deficient viral vectors to deliver full-length HPV antigens, triggering robust CD8+ T cell immune responses capable of targeting and eliminating HPV-infected and cancerous cells. The company is backed by the Danish Innovation Fund, BioInnovation Institute, and the European Commission's Women TechEU program, and is headquartered in Copenhagen, Denmark.

Resilience scores

Technology vendors

Insights

Last updated 2026-09-13 · revision 2

8 direct vendors, 122 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 4/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Loma Therapeutics' migration readiness is assessed as low to moderate, primarily due to several significant challenges. The internal tech stack, centered on WordPress, suggests a more traditional, potentially monolithic architecture rather than a cloud-native, containerized, or microservices-based environment. This will likely necessitate substantial re-platforming or re-architecting efforts for a modern cloud migration, increasing complexity and cost. The company operates under a stringent regulatory environment, including FDA and HIPAA compliance, which mandates careful consideration of data handling, security, and validation during any migration, particularly for clinical trial data and patient health information. Data residency requirements stipulate that data is transferred to and processed in the United States, which limits flexibility in cloud provider and region selection. Financial stability is a concern, as the company is clinical-stage with no public revenue trends, implying potential constraints on funding a significant migration project. A critical unknown is the 'Vendor Lock-in Risk' for its 9 services. If there is high lock-in with existing vendors, it could significantly impede the ability to migrate or switch providers without incurring substantial penalties or operational disruptions. While the company is relatively young, which could imply less legacy debt, the current tech stack and regulatory landscape present considerable hurdles for a smooth and efficient migration.

Compliance

12 in-scope frameworks identified; showing 3.

EU Intellectual Property — Assessment Required

Loma Therapeutics' core asset is its proprietary HPV-targeted immunotherapy technology (Loma001). Patent protection is critical for commercial viability and investor confidence. The company's co-founders are listed as co-inventors of the Loma therapy, suggesting patent applications are likely filed or in preparation. Risk is Medium as IP protection gaps could undermine the company's competitive position and licensing potential, but this is a business risk rather than a regulatory compliance risk per se.

Evidence: https://lomatherapeutics.com, https://www.epo.org/, https://www.dkpto.org/en/

EU GMP — Assessment Required

GMP compliance is mandatory for the manufacture of investigational medicinal products (IMPs) used in clinical trials and for any commercial manufacturing. As Loma advances CMC (Chemistry, Manufacturing, and Controls) activities – explicitly mentioned in the second Innobooster grant announcement – GMP compliance at manufacturing sites becomes critical. The appointment of a CMC Manager (Gaurav Gupta, PhD) signals active CMC development. Non-compliance with GMP can result in clinical trial suspension, product recalls, and regulatory sanctions. Risk is High as manufacturing quality is foundational to clinical and commercial success.

Evidence: https://lomatherapeutics.com, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/quality-guidelines/good-manufacturing-practice, https://laegemiddelstyrelsen.dk/en/licensing/manufacturing/

ISO 27001 (source) — Assessment Required

ISO 27001 is an internationally recognized information security standard that, while voluntary, is increasingly expected in the pharmaceutical and clinical research sector. Loma Therapeutics handles sensitive intellectual property (novel immunotherapy formulations, pre-clinical data, genetic sequences), confidential research data, and will handle clinical trial data as it progresses. Partners such as the Technical University of Denmark and Kingdom Hospital of Denmark, as well as potential future clinical research organizations (CROs) and pharmaceutical partners, may require ISO 27001 certification as a condition of collaboration. The risk is Medium because: (1) the company's IP represents its core asset and is at risk without formal ISMS; (2) pharmaceutical industry norms increasingly require ISO 27001 for data integrity; (3) the company is small and may lack formal security controls. No certification evidence found.

Evidence: https://lomatherapeutics.com, https://www.iso.org/isoiec-27001-information-security.html

Financials

Three-year financials

Financial Resilience Score: 5/10

Loma Therapeutics is an early-stage, pre-clinical Danish biotech spun out around 2023 with no commercial revenue and an expected negative operating result typical of research-stage ApS entities. Its financial position depends almost entirely on non-dilutive grant funding and incubator support rather than product cash flows, so traditional financial resilience metrics (revenue growth, EBIT, equity buffers) are not meaningful at this stage. That said, the company has demonstrated notable success in securing non-dilutive capital: two Innovation Fund Denmark Innobooster grants (most recent DKK 5M / ~€670K in June 2026), an Innovation Fund Denmark Grand Solutions grant with DTU and Rigshospitalet (June 2025), a European Commission Women TechEU grant (2024), and membership in the BioInnovation Institute Venture House Program (September 2024). Combined with a newly established board (Feb 2025) featuring experienced life-science operators and blue-chip scientific advisors including Dr. John T. Schiller (co-inventor of the HPV vaccine), the company appears well-positioned to raise an institutional Series A. However, cash-runway risk remains the dominant financial risk. The company is pre-revenue with a 6–10+ year path to potential product approval, has a single-modality pipeline (HPV adenoviral-vector immunotherapy), and faces meaningful clinical and regulatory binary risk. Overall resilience is moderate — strong for its stage due to grant traction and credible backers, but fundamentally fragile in absolute terms.

Key strengths: Multiple non-dilutive grants: two Innobooster grants (latest DKK 5M), Grand Solutions grant, Women TechEU grant, BioInnovation Institute (BII) Venture House Program membership providing infrastructure and seed capital, Blue-chip scientific advisors including Dr. John T. Schiller (NCI, HPV vaccine co-inventor) and Dr. David Curiel, Experienced board established Feb 2025 (Alejandra Mørk as Chair; Stuart Collinson, Ralf Wagner) signaling Series A readiness, Peer-reviewed publications in Cancer Immunology Research and Cancers providing external validation, Partnerships with DTU and Rigshospitalet

Risk factors: Pre-revenue, pre-clinical stage with no product cash flows expected for many years, Heavy reliance on grants and future equity rounds — cash-runway risk is dominant, Single-modality pipeline concentration (HPV vector immunotherapy), Competitive field with established players (ISA Pharmaceuticals, Nykode, Transgene, Inovio), Small team of ~7 with key-person dependency on founding scientists, Regulatory and clinical binary risk — first-in-human trial not yet initiated, Typical 6–10+ year clinical development timeline to potential approval

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report